AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01562899
Drug: MEK162
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
Trial: NCT00072553
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00072553
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00072553
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03764683
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo capsules (containing no active substance) identical in appearance to those containing Suvorexant
Trial: NCT01542931
Drug: TPF induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
Trial: NCT03676231
Drug: SGM-1019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active
Trial: NCT03676231
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive
Trial: NCT00006400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo.
Trial: NCT01538927
Drug: Suture
RxNorm normalized name: SUTURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Black silk 000
Trial: NCT00170911
Drug: AAE581
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00610883
Drug: LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LSA4 intervention includes three phases: induction, consolidation and maintenance
Trial: NCT03975205
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: To measure bioavailabity of Doxil versus Doxorubicin
Trial: NCT02709096
Drug: BPX-01, 1% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel, applied to the forehead, cheeks, nose and chin
Trial: NCT02865161
Drug: NISELAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NISELAT 600MG BD
Trial: NCT02696785
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01302899
Drug: Placebo to Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HCTZ 25mg (Capsule) Matching Placebo
Trial: NCT02513550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SQ
Trial: NCT00894153
Drug: chemotherapy plus p53
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy plus p53
Trial: NCT00894153
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chemotherapy
Trial: NCT02049164
Drug: AR08
RxNorm normalized name: Arimistane
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02049164
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02330146
Drug: RCT-01
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02330146
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02637973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT00612820
Drug: GSK256066
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mcg bd,
Trial: NCT00275262
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
Trial: NCT00709696
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
Trial: NCT04497142
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Predetermined standard of care drug and dosing
Trial: NCT03081052
Drug: iEPO
RxNorm normalized name: LIMONENE DIEPOXIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive inhaled Epoprostrenol in this intervention
Trial: NCT04153123
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02784054
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04061447
Drug: susceptibility-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days.
Trial: NCT04061447
Drug: empirical clarithromycin-based triple therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The eradication regimen was based on the susceptibility results of gastric PCR. If clarithromycin was sensitive, the regimen contained rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and clarithromycin 500mg B.I.D for seven days. If clarithromycin was resistant and levofloxacin was sensitive, the regimen was rabeprazole 20mg B.I.D, amoxicillin 1000mg B.I.D, and levofloxacin 500mg QD for seven days. If clarithromycin and levofloxacin were both resistant, the regimen was either reverse-hybrid therapy (rabeprazole 20mg B.I.D x 14 days, amoxicillin 1000mg B.I.D, x 14 days, clarithromycin 500mg B.I.D for 7 days, and metronidazole 500mg B.I.D for 7 days) or high dose dual therapy (rabeprazole 20mg Q.I.D and amoxicillin 1000mg Q.I.D for 14 days). Owing to this open design, either reverse-hybrid therapy or high dose dual therapy was chosen by doctors' preference.
Trial: NCT02423928
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
Trial: NCT00040677
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
Trial: NCT03182907
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
Trial: NCT00690443
Drug: AEGR-733
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
Trial: NCT02157922
Drug: alginate oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation
Trial: NCT00095732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally in either Size 2 or Size 5 capsules
Trial: NCT03173573
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for FDL176
Trial: NCT03527173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).
Trial: NCT00932113
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.~Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.
Trial: NCT00504660
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
Trial: NCT00504660
Drug: Celecoxib (Celebrex)
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
Trial: NCT02148549
Drug: FIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
Trial: NCT00002735
Drug: Induction chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and 5-Fluorouracil
Trial: NCT00002735
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
Trial: NCT03182725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A substance that has no therapeutic effect and will act as a control.
Trial: NCT00706433
Drug: aminolevulinic acid HCL (ALA)
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
Trial: NCT00675090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to match once a day
Trial: NCT00448279
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule and dose at the investigator's discretion
Trial: NCT00489073
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00884494
Drug: Ghrelin infusion to assess effects on insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02999126
Drug: Remifentanil Hydrochloride
RxNorm normalized name: Remifentanil Hydrochloride
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
Trial: NCT03843931
Drug: Intra-articular saline injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible.
Trial: NCT01292525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group.
Trial: NCT02593409
Drug: TDF/FTC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
Trial: NCT01703104
Drug: Paludrine + Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This is the combination of routine drugs for treating sickle cell disease
Trial: NCT00787878
Drug: No treatment given
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated SGA
Trial: NCT00787878
Drug: No treatment given
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGA (Average gestational age)
Trial: NCT00458991
Drug: Dextromethorphan and Caffeine
RxNorm normalized name: bupropion and dextromethorphan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH.
Trial: NCT04942262
Drug: denture adhesive (Polident®, GlaxoSmithKline, Ireland)
RxNorm normalized name: ALCOHOL,DENATURED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream-type denture adhesive available as an over-the-counter product in Thailand
Trial: NCT00472420
Drug: First line chemotherapy
RxNorm normalized name: Gallus gallus gizzard lining preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT00875316
Drug: Cogane™ (PYM50028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally active neurotrophic factor inducer
Trial: NCT04494646
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily administration of matching placebo
Trial: NCT04528927
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg (1st day) then 250 mg / D for 4 days
Trial: NCT04528927
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg per day for 10 days
Trial: NCT01927029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03182907
Drug: Antibacterial drug treatment (ABD)
RxNorm normalized name: Dermoplast Antibacterial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABD will be administered for 10-21 days including the duration of ABD prior to the screening visit, during the screening period, and after the infusion of study treatment, per institutional guidelines, at the investigator's discretion. ABD is defined as the receipt of oral metronidazole, oral vancomycin, intravenous (IV) metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
Trial: NCT01186861
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered at least 2 hours after food with up to 200 mL of water
Trial: NCT02613897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00654940
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, matched capsules, BID
Trial: NCT02910154
Drug: Medication (with statin and ACE-inhibition)
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure \> 130 and/or low density lipoprotein (LDL) \> 2.0.
Trial: NCT01879293
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00035958
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00138671
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Trial: NCT00138671
Drug: Inhaled Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Trial: NCT01710462
Drug: Pantozol®
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00174512
Drug: GTN
RxNorm normalized name: GTN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01543529
Drug: RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of RO4917838
Trial: NCT01924533
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
Trial: NCT02595658
Drug: Rapid-Acting Insulin Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02500251
Drug: Plasmapheresis
RxNorm normalized name: HAEMO-PAK UNIT FOR PLASMAPHERESIS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasmapheresis will be administered per study protocol.
Trial: NCT01543529
Drug: Placebo to RO4917838
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo to RO4917838
Trial: NCT02202382
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
Trial: NCT01924520
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01062906
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
Trial: NCT01538329
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg / day once daily in the morning and at noon - oral administration -
Trial: NCT01142596
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
Trial: NCT02169453
Drug: BIA 9-1067
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OPC, Opicapone
Trial: NCT02169453
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLC, Placebo
Trial: NCT02169453
Drug: Sinemet® CR 100/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release levodopa/carbidopa 100/25 mg
Trial: NCT01751074
Drug: Rosuvastatin 10 mg
RxNorm normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
Trial: NCT01789736
Drug: AR-12286 Ophthalmic Solution 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AR-12286 Ophthalmic Solution 0.5%
Trial: NCT02573714
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes \> 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
Trial: NCT00928447
Drug: rHuPH20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 milliliter (mL) Intradermal (ID) syringe push bolus injection of rHuPH20
Trial: NCT00928447
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mL ID syringe push bolus injection of placebo control
Trial: NCT03356457
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A Placebo oral capsule identical in shape and color to those with active ingredient.
Trial: NCT01588496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT02238522
Drug: ZEN003365
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00861523
Drug: thiamine & promethazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiamine 100 mg IV promethazine 25 mg IV
Trial: NCT02739295
Drug: NaCl 0.9%
RxNorm normalized name: DEXTROSE 5%/NACL 0.9% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002565
Drug: CHOP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002565
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002565
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no